Skip to content
value.today

bioAffinity Technologies, Inc.

🇺🇸 San Antonio, Texas, USABiotechnologyFounded 2014
Total raised
$4 M
1 round on record
Latest round
$4 M
Jul 2017
First round on record
Jul 2017
Today
Went public
See the company page

bioAffinity Technologies, Inc. is listed today as bioAffinity Technologies, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of bioAffinity Technologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$1 MPrivate placement after listingUnder $2 million

bioAffinity Technologies, Inc.: Private sale, Aug 2024

Investors in this round

3 investors had bought by the notice of Aug 12, 2024: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for bioAffinity Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$104,167
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maria Zannes · Executive Officer, Director · Chief Executive Officer
  • Michael Dougherty · Executive Officer · Chief Financial Officer
  • Timothy P. Zannes · Executive Officer · Executive VP and Secretary
  • Vivienne Rebel · Executive Officer · Chief Science and Medical Officer
  • Xavier Reveles · Executive Officer, Director · Chief Operating Officer
  • Gary P. Rubin · Director
  • Jamie P. Platt · Director
  • Peter A. Knight · Director
  • Robert A. Anderson · Director
  • Roby P. Joyce · Director
  • Steven P. Girgenti · Director
  • Stuart A. Diamond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • WallachBeth Capital LLC (CRD 000147853) · Boca Raton, FloridaSold in FL, NV, NY

Remarks in the notice

  • On fees: “Placement agent fee of 8% plus warrants to purchase up to 39,062 shares of common stock at an exercise price of $1.50.”
  • On the amounts: “Offering proceeds from exercise of warrants pursuant to a Warrant Inducement Letter Agreement”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Maria Zannes, President & CEO. Source: SEC Form D, newest notice filed Aug 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Mar 2024$3 MPrivate placement after listing$2 to $10 million

bioAffinity Technologies, Inc.: Private sale, Mar 2024

Investors in this round

3 investors had bought by the notice of Mar 20, 2024: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for bioAffinity Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$2,624,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$225,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maria Zannes · Executive Officer, Director
  • Michael Dougherty · Executive Officer · Placement agent fee of 9% plus warrants to purchase 32,000 shares at an exercise price of $1.64.
  • Steven P. Girgenti · Executive Officer, Director
  • Timothy P. Zannes · Executive Officer
  • Vivienne Rebel · Executive Officer
  • Jamie P. Platt · Director
  • Roby P. Joyce · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • WallachBeth Capital LLC (CRD 147853) · Boca Raton, FloridaSold in CA, NY

Remarks in the notice

  • On fees: “Placement agent fee of 9% plus warrants to purchase 32,000 shares at an exercise price of $1.64.”
  • On the amounts: “Includes an aggregate exercise price of warrants of $1.64”

Signed by Maria Zannes, President & CEO. Source: SEC Form D, newest notice filed Mar 20, 2024. Read the notice at the SEC.

equity, optionsSEC
Jul 2017$4 MNo. 1$2 to $10 million

bioAffinity Technologies, Inc.: Raise no. 1, Jul 2017

Investors in this round

39 investors had bought by the notice of Jul 26, 2017: 26 accredited, 13 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for bioAffinity Technologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Maria Zannes · Executive Officer, Director
  • Barry Frankel · Director
  • Myron Holubiak · Director
  • Robert Anderson · Director
  • Steven Girgenti · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be paid toward the salary of the person named in Item 3.”

Signed by Maria Zannes, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 26, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • bioAffinity Technologies, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).

    SEC Form D · Aug 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2024

That is all the official record says: bioAffinity Technologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of bioAffinity Technologies, Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in bioAffinity Technologies, Inc.
InvestorKindAmountRoundRoleSource
Harvey Sandler Revocable TrustOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Mohsin Y. MeghjiPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2023)SEC Form 3
Nathan M. PerlmutterPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Steven GirgentiPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 39 investors.

Largest shareholders today

Institutions holding bioAffinity Technologies, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by bioAffinity Technologies, Inc.
NameRoleNamed in
Maria ZannesChief Executive OfficerAug 2024
Michael DoughertyChief Financial OfficerAug 2024
Timothy P. ZannesExecutive VP and SecretaryAug 2024
Vivienne RebelChief Science and Medical OfficerAug 2024
Xavier RevelesChief Operating OfficerAug 2024
Steven P. GirgentiExecutive officerMar 2024
Gary P. RubinDirectorAug 2024
Jamie P. PlattDirectorAug 2024
Maria ZannesChief Executive OfficerAug 2024
Peter A. KnightDirectorAug 2024
Robert A. AndersonDirectorAug 2024
Roby P. JoyceDirectorAug 2024
Steven P. GirgentiDirectorAug 2024
Stuart A. DiamondDirectorAug 2024
Xavier RevelesChief Operating OfficerAug 2024
Barry FrankelDirectorJul 2017
Myron HolubiakDirectorJul 2017
Robert AndersonDirectorJul 2017
Steven GirgentiDirectorJul 2017

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.